alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 15,426–15,450 of 15,839 studies scoring 30–49 out of 100 (page 618 of 634) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

PDE4A knockdown rescues alcohol-induced cognitive impairment and synaptic dysfunction via the cAMP/PKA/CREB pathway

✓ Peer-reviewed alzhub usefulness score 33 out of 100. The International Journal of Neuropsychopharmacology 2026-07-01

This study demonstrated that selectively targeting PDE4A rescued cognitive and neuropathological deficits in a validated mouse model of AlD. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Targeting Metabolic Dysregulation in Alzheimer’s Disease: A Potential Therapeutic Strategy

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Current Drug Metabolism 2025-09-01

Alzheimer's disease (AD), the most common form of dementia, is characterized by progressive cognitive decline and neuropathological hallmarks, including amyloid-beta plaques and tau tangles. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Ideggyógyászati Szemle 2025-01-01

Neurogranin levels were significantly reduced in MTLE-HS patients as compared to FLE patients and healthy controls but were not correlated with any of the clinical and cognitive variables. 5 key findings →

Participants: 51 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Extracellular Vesicles in Alzheimer’s Disease: Mechanisms, Immunotherapy Links, and Clinical Translation

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Current Pharmaceutical Design 2026-05-13

Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by synaptic dysfunction, neuroinflammation, and cognitive impairment. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cognitive–exercise dual-task training delays natural aging/d-galactose-induced cognitive decline in mice

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Cellular & Molecular Biology Letters 2026-01-23

Age-related upregulation in microRNA (miR)-204 and downregulation in long noncoding RNA (lncRNA) nuclear enriched abundant transcript 1 (NEAT1) were observed to disrupt Ephrin-B1 (EFNB1)/EphB2 interactions, leading to reduced cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway activation. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Beneficial Effects of Water-Based Exercise Alone and in Combination with Cognitive Training on Cardiovascular Fitness and Arterial Stiffness in Older Adults with Mild Cognitive Impairment: A Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Life 2025-07-28

Mild cognitive impairment (MCI) is the transitional stage between normal cognition and dementia and is associated with arterial stiffness, which may lead to cardiovascular disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Can a Mediterranean diet prevent cognitive decline?

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2025-11-11

Current evidence suggests a potential for the Mediterranean diet to prevent cognitive decline, largely supported by observational studies, although randomized controlled trials show mixed results. 1 key finding →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Navigating Dementia and Delirium: Balancing Identity and Interests in Advance Directives

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Nursing Philosophy 2025-01-01

The moral authority of advance directives (ADs) in the context of persons living with dementia (PLWD) has sparked a multifaceted debate, encompassing concerns such as authenticity and the appropriate involvement of caregivers. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Delirium as a Precursor to Dementia in Elderly Type 2 Diabetes Mellitus Patients

✓ Peer-reviewed alzhub usefulness score 33 out of 100. The Journal of Clinical Psychiatry 2025-05-16

This study aimed to investigate the association between delirium and incident dementia in elderly (≥65 years) type 2 diabetes mellitus (T2DM) patients, addressing the heightened dementia risk in this population. newly diagnosed between January 1, 2005, and December 31, 2007. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The historical and projected prevalence of dysphagia in Aotearoa New Zealand

✓ Peer-reviewed alzhub usefulness score 33 out of 100. New Zealand Medical Journal 2025-02-27

The prevalence of dysphagia in Aotearoa New Zealand is estimated to have been approximately 1.78% in 2020, with the biggest aetiological contributors being stroke, Alzheimer's disease and other dementias, and gastroesophageal reflux disease. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Using a collaborative approach to reduce falls in older people’s adult mental health wards in a local health board in Wales

✓ Peer-reviewed alzhub usefulness score 33 out of 100. BMJ Open Quality 2025-04-01

Between April 2020 and March 2021, the number of fall-related emergency admissions in England for adults over 65 years was 1933 per 100 000 people. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Early recognition of delirium in hospitalized patients: an underutilized clinical priority

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Annals of Medicine and Surgery 2026-06-08

Importantly, delirium is not merely a transient cognitive fluctuation; it is independently associated with increased short- and long-term mortality, longer hospital stays, higher healthcare costs, and persistent cognitive impairment comparable to mild dementia[4,5]. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Smart Room Design for Dementia Nursing Home Based on Kano-AHP-QFD Integrated Methodology

✓ Peer-reviewed alzhub usefulness score 33 out of 100. HERD Health Environments Research & Design Journal 2025-08-28

BackgroundWith the growing demand for dementia-friendly care environments, existing smart room designs often lack systematic methods to translate user needs into functional solutions. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Behavioral Variant Frontotemporal Dementia With C9orf72 Intermediate Repeat Expansion

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer Disease & Associated Disorders 2026-01-01

Hexanucleotide repeat expansion in the chromosome 9 open reading frame 72 ( C9orf72 ) gene has been identified as the most common genetic cause of both frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

‘It should be my choice’: voluntary assisted dying needs and preferences of Australians living with dementia

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Ageing and Society 2025-09-24

Voluntary assisted dying (VAD) is an end-of-life care option available to eligible Australians living with a terminal condition, though people living with dementia are typically ineligible to choose VAD as part of their end-of-life care. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed